The authors propose OpenIO (Open Immune Oncology), a conceptual framework that integrates generative AI, biological scaling laws, foundation models, and omics data to advance precision immunotherapy.
No empirical results are reported; this is a framework/perspective paper proposing a shift from empirical immunotherapy screening to rational, AI-native engineering of therapeutic interventions.
No experimental data, patient cohorts, or clinical validation are presented. The framework remains theoretical at this stage, with real-world feasibility and generalizability yet to be demonstrated.
Explore related topics
